{"id":"NCT00736879","sponsor":"AstraZeneca","briefTitle":"Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09-22","primaryCompletion":"2009-12-29","completion":"2009-12-29","firstPosted":"2008-08-18","resultsPosted":"2014-05-02","lastUpdate":"2017-04-20"},"enrollment":497,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148","Farxigaâ„¢"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dapagliflozin 1 mg","type":"EXPERIMENTAL"},{"label":"Dapagliflozin 2.5 mg","type":"EXPERIMENTAL"},{"label":"Dapagliflozin 5 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on diet and exercise alone. The safety of this treatment will also be studied","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants","timeFrame":"Baseline (Day 1), Week 24","effectByArm":[{"arm":"Placebo","deltaMin":0.02,"sd":0.12},{"arm":"Dapagliflozin 1mg","deltaMin":-0.68,"sd":0.1166},{"arm":"Dapagliflozin 2.5 mg","deltaMin":-0.72,"sd":0.1169},{"arm":"Dapagliflozin 5 mg","deltaMin":-0.82,"sd":0.1217}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":62,"countries":["United States","Canada","India","Mexico","Puerto Rico","Russia","South Africa"]},"refs":{"pmids":["26894924"],"seeAlso":["http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":72},"commonTop":["Headache","Nasopharyngitis","Pharyngitis","Dizziness","Hypertriglyceridaemia"]}}